Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label, Single Arm, Multi-centre, Phase II Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin With Superficial and Interstitial Laser Light Application in Patients With Recurrent Head and Neck Cancer

Next Previous
Trial Profile

Open-label, Single Arm, Multi-centre, Phase II Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin With Superficial and Interstitial Laser Light Application in Patients With Recurrent Head and Neck Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fimaporfin (Primary) ; Fimaporfin/gemcitabine (Primary) ; Bleomycin
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Acronyms ENHANCE
  • Sponsors PCI Biotech

Most Recent Events

  • 08 Jun 2015 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
  • 22 Dec 2014 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
  • 22 Dec 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top